SAM
CHRS icon

Shell Asset Management’s Coherus Oncology CHRS Stock Holding History

Shell Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,137
Closed -$7K – 1172
2025
Q2 		$7K Sell
9,137
-7,847
-46% -$6.78K ﹤0.01% 1257
2025
Q1 		$14K Sell
16,984
-570
-3% -$656 ﹤0.01% 1240
2024
Q4 		$24K Hold
17,554
– – ﹤0.01% 1235
2024
Q3 		$18K Buy
+17,554
New +$24.1K ﹤0.01% 1240
2024
Q1 		$26K Sell
15,069
-1,015
-6% -$2.5K ﹤0.01% 1218
2023
Q4 		$54K Sell
16,084
-4,830
-23% -$12.9K ﹤0.01% 1163
2023
Q3 		$78K Sell
20,914
-329
-2% -$1.52K ﹤0.01% 1129
2023
Q2 		$91K Sell
21,243
-122
-0.6% -$720 ﹤0.01% 1138
2023
Q1 		$146K Sell
21,365
-75
-0.3% -$582 0.01% 1022
2022
Q4 		$170K Sell
21,440
-4,353
-17% -$33.5K 0.01% 1005
2022
Q3 		$248K Sell
25,793
-6,760
-21% -$68.4K 0.01% 922
2022
Q2 		$236K Buy
32,553
+55
+0.2% +$478 0.01% 1067
2022
Q1 		$420K Sell
32,498
-4,809
-13% -$61.2K 0.01% 891
2021
Q4 		$595K Buy
37,307
+179
+0.5% +$3.13K 0.01% 821
2021
Q3 		$597K Sell
37,128
-1,600
-4% -$23.5K 0.01% 785
2021
Q2 		$536K Buy
38,728
+2,100
+6% +$29.7K 0.01% 879
2021
Q1 		$535K Buy
36,628
+18,859
+106% +$320K 0.01% 821
2020
Q4 		$309K Buy
+17,769
New +$316K 0.01% 994

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Shell Asset Management's CHRS Position: Q3 2025 in Review

Shell Asset Management sold out of Coherus Oncology (CHRS) in Q3 2025, closing a stake of 9,137 shares — an estimated $7K sold.

Shell Asset Management first reported a position in CHRS in Q4 2020 and held it in 18 quarters. The position peaked at $597K in Q3 2021. 114 funds tracked by Wall St. Rank hold CHRS as of Q3 2025.

  • Shell Asset Management reported no remaining Coherus Oncology position as of Q3 2025 after selling out during the quarter.
  • Shell Asset Management sold 9,137 Coherus Oncology shares in Q3 2025, an estimated $7K.
  • Shell Asset Management first reported a position in Coherus Oncology in Q4 2020 and held it in 18 quarters.
  • Shell Asset Management's Coherus Oncology position peaked at $597K in Q3 2021.
  • 114 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.